PMID- 29672849
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20220408
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Print)
IS  - 0021-9541 (Linking)
VI  - 233
IP  - 10
DP  - 2018 Oct
TI  - Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), 
      platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer 
      (NSCLC) treated with Nivolumab or Docetaxel.
PG  - 6337-6343
LID - 10.1002/jcp.26609 [doi]
AB  - Nivolumab is a novel therapeutic option in NSCLC, associated with a significant 
      survival gain compared with Docetaxel. However, predictive biomarkers are 
      lacking. The presence of systemic inflammation has been correlated with poor 
      outcome in many cancer types. We aimed to evaluate whether there is a correlation 
      between some indicators of inflammation and response to Nivolumab or Docetaxel in 
      pre-treated NSCLCs. Data of 62 patients receiving Nivolumab or Docetaxel were 
      analyzed. Baseline neutrophilia and thrombocytosis were not associated with 
      response. High dNLR was associated with no response to Nivolumab, but not with 
      Docetaxel, whereas high PLR correlated with low treatment response in both 
      groups. Among refractory patients, a higher incidence of thrombocytosis, 
      neutrophilia, high PLR, and high dNLR levels were observed compared with the 
      overall population. This is one of the first reports in this field and suggests 
      that indicators of inflammation might be included together with other predictive 
      biomarkers in the baseline evaluation of patients candidate for immunotherapy.
CI  - (c) 2018 The Authors. Journal of Cellular Physiology Published by WileyPeriodicals, 
      Inc.
FAU - Russo, Alessandro
AU  - Russo A
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
FAU - Franchina, Tindara
AU  - Franchina T
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
FAU - Ricciardi, Giuseppina R R
AU  - Ricciardi GRR
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
FAU - Battaglia, Alessandra
AU  - Battaglia A
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
FAU - Scimone, Antonino
AU  - Scimone A
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
FAU - Berenato, Rosa
AU  - Berenato R
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
FAU - Giordano, Antonio
AU  - Giordano A
AD  - Department of Medicine, Surgery and Neuroscience, University of Siena and 
      Istituto Toscano Tumori (ITT), Siena, Italy.
AD  - Sbarro Institute for Cancer Research and Molecular Medicine, Center for 
      Biotechnology, College of Science and Technology, Temple University, 
      Philadelphia, Pennsylvania.
FAU - Adamo, Vincenzo
AU  - Adamo V
AUID- ORCID: 0000-0003-2074-2418
AD  - Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of 
      Messina, Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180419
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (Biomarkers, Tumor)
RN  - 15H5577CQD (Docetaxel)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - Blood Platelets/pathology
MH  - Carcinoma, Non-Small-Cell Lung/blood/*drug therapy/pathology
MH  - Docetaxel/administration & dosage/adverse effects
MH  - Drug-Related Side Effects and Adverse Reactions/blood/pathology
MH  - Female
MH  - Humans
MH  - Inflammation/blood/*drug therapy/pathology
MH  - Lymphocytes/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neutrophils/*pathology
MH  - Nivolumab/administration & dosage/adverse effects
MH  - Prognosis
MH  - Treatment Outcome
PMC - PMC6767577
OTO - NOTNLM
OT  - NSCLC
OT  - Nivolumab
OT  - biomarker
OT  - neutrophil-to-lymphocyte ratio
OT  - platelet-to-lymphocyte ratio
COIS- No potential conflicts of interest declared.
EDAT- 2018/04/20 06:00
MHDA- 2019/10/01 06:00
PMCR- 2019/09/30
CRDT- 2018/04/20 06:00
PHST- 2018/01/20 00:00 [received]
PHST- 2018/03/22 00:00 [accepted]
PHST- 2018/04/20 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
PHST- 2018/04/20 06:00 [entrez]
PHST- 2019/09/30 00:00 [pmc-release]
AID - JCP26609 [pii]
AID - 10.1002/jcp.26609 [doi]
PST - ppublish
SO  - J Cell Physiol. 2018 Oct;233(10):6337-6343. doi: 10.1002/jcp.26609. Epub 2018 Apr 
      19.